KIF5A upregulation in hepatocellular carcinoma: A novel prognostic biomarker associated with unique tumor microenvironment status

• Published in: Frontiers in oncology Vol. 12; p. 1071722
• Main Authors: Liu, Qi, Liu, Yu-yang, Chen, Xue-min, Tao, Bing-yan, Chen, Kuang, Li, Wei-min, Xu, Chang-tao, Shi, Ying, Li, Hao, Liu, Hao-run
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06.01.2023
• Subjects: immunotherapy; KIF5A; liver hepatocellular carcinoma; Oncology; prognostic biomarker; tumor microenvironment; prognostic biomarker; liver hepatocellular carcinoma; tumor microenvironment; KIF5A; immunotherapy
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.1071722

Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a microtubule-based motor protein involved in the transport of macromolecules such as organelle proteins in cells. Recent studies have illustrated that the high expression of KIF5A was related to poor prognosis of solid tumors, including bladder cancer, prostate cancer, and breast cancer. However, little is currently known concerning the clinical significance of KIF5A expression in LIHC. Herein, by adopting multi-omics bioinformatics analysis, we comprehensively uncovered the potential function and the predictive value of KIF5A in stratifying clinical features among patients with LIHC, for which a high KIF5A level predicted an unfavorable clinical outcome. Results from KIF5A-related network and enrichment analyses illustrated that KIF5A might involve in microtubule-based process, antigen processing and presentation of exogenous peptide antigen via MHC class II. Furthermore, immune infiltration and immune function analyses revealed upregulated KIF5A could predict a unique tumor microenvironment with more CD8+T cells and a higher level of anti-tumor immune response. Evidence provided by immunohistochemistry staining (IHC) further validated our findings at the protein level. Taken together, KIF5A might serve as a novel prognostic biomarker for predicting immunotherapy response and could be a potential target for anti-cancer strategies for LIHC.